Market Place
Sourcing Support
Mission Therapeutics Receives $5.2M For Parkinson`s Treatment MTX325
02 Jul 2024 //
PR NEWSWIRE
Pfizer-backed UK biotech raises £25M to advance mitophagy pipeline
14 Mar 2024 //
ENDPTS
Mission Therapeutics announces FDA approval to initiate PII trial of MTX652
14 Dec 2023 //
PR NEWSWIRE
Mission Therapeutics granted MHRA Clinical Trial Authorisation (CTA) for MTX325
05 Dec 2023 //
PR NEWSWIRE
Mission announces publication outlining potential of experimental drug MTX325
13 Nov 2023 //
PR NEWSWIRE
Mission Therapeutics to Present Abstract at ASN Kidney Week 2023
02 Nov 2023 //
PR NEWSWIRE
Mission Therapeutics to Present at Michael J. Fox Foundation`s Conference
10 Oct 2023 //
PR NEWSWIRE
Mission Therapeutics Successfully Completes First Assessment for MTX652
05 Jan 2023 //
BUSINESSWIRE
Mission Therapeutics concludes clinical assessment for lead DUB inhibitor
05 Jan 2023 //
PHARMA TIMES
Mission Therapeutics to Present at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
BUSINESSWIRE
Mission Therapeutics launches clinical trial for kidney disease therapy
31 Mar 2022 //
PHARMATIMES
Mission Tx Authorised to Initiate 1st Trial for MTX652, in Kidney Disease
31 Mar 2022 //
BUSINESSWIRE
Mission, awarded follow-on Therapeutic Pipeline Programme grant from MJFF
13 Oct 2021 //
PHARMABIZ
AbbVie picks Alzheimer`s, Parkinson`s targets for Mission pact
10 Aug 2021 //
FIERCEBIOTECH
Mission and AbbVie deal in Alzheimer’s and Parkinson Reaches Next Milestone
09 Aug 2021 //
BUSINESSWIRE
Mission Raises $15m and Expands its Relationship with Pfizer
06 Jul 2020 //
BUSINESSWIRE
Pfizer re-ups on Mission Therapeutics collaboration, leading a $15M round
06 Jul 2020 //
ENDPTS
Mission Raises $15m and Expands its Relationship with Pfizer
06 Jul 2020 //
BUSINESSWIRE
Mission and AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Milestone
03 Dec 2019 //
BUSINESSWIRE
Mission & AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases
03 Dec 2019 //
BUSINESS WIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.